SMARCA4 and non-small cell lung carcinoma: Despite clinical evidence from a large cohort demonstrating that SMARCA4 genetic co‐alterations are independently associated with poor clinical outcomes in NSCLC patients treated with G12Ci,41 the mechanisms by which SMARCA4 loss may modulate response to G12Ci remain unknown.